Tags

Type your tag names separated by a space and hit enter

Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?
Can J Physiol Pharmacol 2000; 78(10):829-47CJ

Abstract

The demonstration that the trace element vanadium has insulin-like properties in isolated cells and tissues and in vivo has generated considerable enthusiasm for its potential therapeutic value in human diabetes. However, the mechanisms by which vanadium induces its metabolic effects in vivo remain poorly understood, and whether vanadium directly mimics or rather enhances insulin effects is considered in this review. It is clear that vanadium treatment results in the correction of several diabetes-related abnormalities in carbohydrate and lipid metabolism, and in gene expression. However, many of these in vivo insulin-like effects can be ascribed to the reversal of defects that are secondary to hyperglycemia. The observations that the glucose-lowering effect of vanadium depends on the presence of endogenous insulin whereas metabolic homeostasis in control animals appears not to be affected, suggest that vanadium does not act completely independently in vivo, but augments tissue sensitivity to low levels of plasma insulin. Another crucial consideration is one of dose-dependency in that insulin-like effects of vanadium in isolated cells are often demonstrated at high concentrations that are not normally achieved by chronic treatment in vivo and may induce toxic side effects. In addition, vanadium appears to be selective for specific actions of insulin in some tissues while failing to influence others. As the intracellular active forms of vanadium are not precisely defined, the site(s) of action of vanadium in metabolic and signal transduction pathways is still unknown. In this review, we therefore examine the evidence for and against the concept that vanadium is truly an insulin-mimetic agent at low concentrations in vivo. In considering the effects of vanadium on carbohydrate and lipid metabolism, we conclude that vanadium acts not globally, but selectively and by enhancing, rather than by mimicking the effects of insulin in vivo.

Authors+Show Affiliations

Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia,Vancouver, Canada.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

11077984

Citation

Cam, M C., et al. "Mechanisms of Vanadium Action: Insulin-mimetic or Insulin-enhancing Agent?" Canadian Journal of Physiology and Pharmacology, vol. 78, no. 10, 2000, pp. 829-47.
Cam MC, Brownsey RW, McNeill JH. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Can J Physiol Pharmacol. 2000;78(10):829-47.
Cam, M. C., Brownsey, R. W., & McNeill, J. H. (2000). Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Canadian Journal of Physiology and Pharmacology, 78(10), pp. 829-47.
Cam MC, Brownsey RW, McNeill JH. Mechanisms of Vanadium Action: Insulin-mimetic or Insulin-enhancing Agent. Can J Physiol Pharmacol. 2000;78(10):829-47. PubMed PMID: 11077984.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? AU - Cam,M C, AU - Brownsey,R W, AU - McNeill,J H, PY - 2000/11/15/pubmed PY - 2001/6/2/medline PY - 2000/11/15/entrez SP - 829 EP - 47 JF - Canadian journal of physiology and pharmacology JO - Can. J. Physiol. Pharmacol. VL - 78 IS - 10 N2 - The demonstration that the trace element vanadium has insulin-like properties in isolated cells and tissues and in vivo has generated considerable enthusiasm for its potential therapeutic value in human diabetes. However, the mechanisms by which vanadium induces its metabolic effects in vivo remain poorly understood, and whether vanadium directly mimics or rather enhances insulin effects is considered in this review. It is clear that vanadium treatment results in the correction of several diabetes-related abnormalities in carbohydrate and lipid metabolism, and in gene expression. However, many of these in vivo insulin-like effects can be ascribed to the reversal of defects that are secondary to hyperglycemia. The observations that the glucose-lowering effect of vanadium depends on the presence of endogenous insulin whereas metabolic homeostasis in control animals appears not to be affected, suggest that vanadium does not act completely independently in vivo, but augments tissue sensitivity to low levels of plasma insulin. Another crucial consideration is one of dose-dependency in that insulin-like effects of vanadium in isolated cells are often demonstrated at high concentrations that are not normally achieved by chronic treatment in vivo and may induce toxic side effects. In addition, vanadium appears to be selective for specific actions of insulin in some tissues while failing to influence others. As the intracellular active forms of vanadium are not precisely defined, the site(s) of action of vanadium in metabolic and signal transduction pathways is still unknown. In this review, we therefore examine the evidence for and against the concept that vanadium is truly an insulin-mimetic agent at low concentrations in vivo. In considering the effects of vanadium on carbohydrate and lipid metabolism, we conclude that vanadium acts not globally, but selectively and by enhancing, rather than by mimicking the effects of insulin in vivo. SN - 0008-4212 UR - https://www.unboundmedicine.com/medline/citation/11077984/Mechanisms_of_vanadium_action:_insulin_mimetic_or_insulin_enhancing_agent L2 - https://medlineplus.gov/diabetesmedicines.html DB - PRIME DP - Unbound Medicine ER -